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Abstract: Malignant mesothelioma (MM) is a malignant tumor derived from mesothelial cells, native cells of the body 
cavities. Exposure to asbestos is the most strongly established etiologic factor, predominantly for the most common disease 
form, pleural mesothelioma. The pathogenesis of MM involves the accumulation of extensive cytogenetic changes, as well 
as cancer-related phenotypic alterations that facilitate tumor cell survival, invasion and metastasis. This review presents 
current knowledge regarding the biological characteristics of this disease that are linked to the so-called hallmarks of can-
cer. In addition, data suggesting that the anatomic site (solid tumor vs. effusion) affects the expression of metastasis-associ-
ated and regulatory molecules in MM are presented. Finally, recent work in which high-throughput methodology has been 
applied to MM research is reviewed. The data obtained in the reviewed research may aid in deﬁ  ning new prognostic mark-
ers and therapeutic targets for this aggressive disease in the future.
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Introduction
Malignant mesothelioma (MM) is a tumor derived from mesothelial cells, native cells of the body cavi-
ties. The pleural cavity is the most common site, with a present ratio of 9:1 with peritoneal tumors. 
Exposure to asbestos can be documented in about 80% of the cases (Britton, 2002). The incidence of 
MM appears to be rising steeply in western countries, a trend that is likely to continue (Parker, 2003; 
van Ruth, 2003). MM is an aggressive and rapidly fatal disease, with a median survival of 8 months if 
untreated, although selected patients achieve survival of 2 years and more when surgery is combined 
with adjuvant therapy (Parker, 2003; van Ruth, 2003). Validated clinicopathologic prognostic factors 
of poor survival are non-epithelioid tumor type, poor performance status, male gender, high white blood 
cell count and low hemoglobin levels (Burgers, 2004). The disease develops for decades, during which 
the neoplastic cells accumulate a variety of chromosomal aberrations. Extensive studies using traditional 
cytogenetics, analysis of microsatellite instability/loss of heterozygosity and ﬂ  uorescent in situ hybrid-
ization (FISH) have shown that gains or losses of entire chromosomes or chromosome fragments most 
frequently involve chromosomes 1, 3, 6, 7, 9, 14, 18 and 22 (reviewed in Sandberg, 2001; Musti, 2006). 
Use of gene-speciﬁ  c molecular probes has identiﬁ  ed loss of the cyclin-dependent kinase-4 inhibitor 
(CDKN2A) (Prins, 1998; Illei, 2003), neuroﬁ  bromatosis type 2 (NF2) (Bianchi, 1995; Sekido, 1995), 
p15 and p16 (Xio, 1995), p53 (Cote, 1991), and Fhit (Pylkkanen, 2004) genes in MM, supporting the 
role of cell cycle deregulation and inactivation of tumor suppressor genes in its pathogenesis. 
Simian virus 40 (SV40) is an additional postulated contributing factor in the development of MM. 
Some of the Polio vaccines prepared during the 50’s and early 60’s have been shown to be contaminated 
with SV40, a polyomavirus that produces an asymptomatic infection in macaque rhesus monkeys, its 
natural host. Earlier studies have reported high levels of expression of SV40 DNA or large T antigen 
protein in MM (reviewed in Shah, 2006), although not all studies reproduced this observation (Simsir, 
2001; Manfredi, 2005). The presence of SV40 has been associated with expression of several cancer-
associated molecules, the majority of which are discussed below. The presence of SV40 in MM was 
shown to be associated with more frequent methylation of the RASSF1 gene, a putative tumor suppressor 
gene in lung cancer (Toyooka, 2001). SV40 replication was associated with autocrine activation via Biomarker Insights 2007: 2 174
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hepatocyte growth factor/scatter factor (HGF/SF) 
and its receptor Met (Cacciotti, 2001). The pres-
ence of SV40 has been shown to be associated with 
higher levels of vascular endothelial growth factor 
(VEGF) (Cacciotti, 2002), telomerase activity 
(Foddis, 2002), expression of the cell cycle inhib-
itor p21
WAF1/CIP1 (Baldi, 2002), p53 inactivation 
(Carbone, 2003) and activation of the phosphati-
dylinositol 3-kinase/AKT signaling pathway 
(Cacciotti, 2001; Ramos-Nino, 2005). 
The role of SV40 in the pathogenesis of MM 
has been growingly questioned in recent years. 
Twenty-one of 31 papers published in the time 
period from 2002 until the publication of the 
above-mentioned review have failed to ﬁ  nd any 
evidence supporting the presence of SV40 in MM 
or found only rare DNA or protein expression of 
the virus (Shah, 2006). Furthermore, contamination 
with laboratory plasmids has been shown to be a 
frequent source of false-positive results in studies 
analyzing the presence of SV40 (Lopez-Rios, 
2004), and serological studies have shown rare 
seroreactivity for the virus among the general 
population and MM patients, as well as cross-reac-
tivity with the more prevalent BKV and JCV 
polyomaviruses (Shah, 2006). These data suggest 
a need to re-evaluate the role of SV40 in MM. 
Patients with the more common pleural MM 
typically present with cough, dyspnea and chest 
pain, reﬂ  ecting the presence of pleural plaques and 
a characteristically unilateral malignant hemor-
rhagic effusion (Pass, 1993; Moskal, 1998). 
Patients with peritoneal disease present with 
abdominal distention and pain that are caused by 
the presence of malignant cells in ascites and in 
solid peritoneal lesions, a clinical picture that may 
be indistinguishable from that observed in ovarian 
or peritoneal carcinoma (Eltabbakh, 1999; Sugar-
baker, 2003). Although present in a large number 
of cases at autopsy, clinically detectable distant 
metastases are rare at presentation.
The main differential diagnosis of epithelioid 
MM, the most common histologic type, is with 
metastatic adenocarcinoma, most frequently of 
ovarian, breast or lung origin, and reactive meso-
thelium (RM). Benign mesothelial cells react to a 
wide variety of stimuli and injuries by proliferation 
and reactive cellular changes that may mimic the 
morphology of malignant cells (Bedrossian, 1994). 
These changes may be especially pronounced 
following radiation or chemotherapy, common 
adjuncts to surgery in the treatment of various 
malignancies (Bedrossian, 1994). The overlapping 
morphology of these cell types does not allow for 
a reliable diagnosis of MM without the use of 
ancillary techniques. In recent years, immunohis-
tochemistry has largely taken over the role of 
electron microscopy in this ﬁ  eld. While the possi-
bility to diagnose MM in cytological material is 
still not universally accepted, improved antibody 
panels and the use of formalin-ﬁ  xed parafﬁ  n-
embedded cell block material for effusion diag-
nosis have led to results that are at least comparable 
to those observed in surgical specimens, with lesser 
morbidity and cost (Figures 1-A, 1-B) (Bedrossian, 
1998; Davidson, 2001). In fact, the diagnosis of 
MM can be reliably obtained within less than one 
day using ﬂ  ow cytometry, a procedure that is 
optimal for effusion specimens (Davidson, 2002a; 
Sigstad, 2005). Recently, molecular methods such 
as comparative genomic hybridization (CGH) and 
FISH have been successfully used for the diagnosis 
of MM in cytological material (Nagel, 2002; Illei, 
2003). 
Cancer cells show a spectrum of phenotypic 
aberrations, all reﬂ  ecting the loss of host regulation 
and the ability to override checkpoints that allow 
normal tissue to remain in homeostasis. These 
consist of altered cellular adhesion, abnormal 
response to growth-promoting signals, cell cycle 
deregulation and evasion of apoptosis, and enhanced 
proteolysis and angiogenesis (Hanahan, 2000). 
Although the majority of translational correlates that 
are related to chromosomal changes in MM and the 
mechanisms of epigenetic regulation in this disease 
are still undeﬁ  ned, recent research has deﬁ  ned many 
of the phenotypic characteristics of MM that are 
related to the so-called hallmarks of cancer. This 
review presents currently available data regarding 
the cancer-related biology of MM, with focus 
mainly on research performed on clinical specimens. 
Data suggesting that the anatomic site (pleura vs. 
peritoneum) and growth conditions (solid tumor vs. 
effusion) may affect the phenotype of MM cells are 
presented. Finally, recent work in which high-
throughput methodology has been applied to MM 
research is reviewed.
Proteolytic Enzymes
Matrix metalloproteinases (MMP), a family of zinc- 
and calcium-dependent enzymes, are central media-
tors of the biology of tumor invasion and metastasis, 
due to their ability to degrade the basement membrane Biomarker Insights 2007: 2 175
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and essentially all extracellular matrix (ECM) compo-
nents (Egeblad, 2002). Two members of the family, 
MMP-2 and MMP-9, are the proteases involved in 
basement membrane degradation, a major event in 
the dissemination of epithelial cancer. MM cell lines 
have been shown to express and activate MMP-2 and 
MMP-9, and express and secrete several other 
members of this family, including MMP-1, MMP-3, 
MMP-7 and MMP-10, as well as the MMP inhibitors 
TIMP1-3 (Liu, 2001). MMP expression and secretion 
by MM cells in vitro is increased by several growth 
factors, including HGF/SF (Harvey, 2000; Liu, 2003), 
epidermal growth factor (EGF), acidic and basic 
ﬁ  broblast growth factor (aFGF, bFGF), insulin-like 
growth factors I and II (IGF-I,II) and transforming 
growth factor-α (TGF- α) (Liu, 2003). MMP-2 and 
MMP-9 activity, as measured by gelatin zymography, 
was documented in clinical MM specimens, with 
predominant activation of the former enzyme. MMP-
9 activity was signiﬁ  cantly higher than in benign 
pleura, and MMP-2 was an independent predictor of 
poor survival (Edwards, 2003). Our group recently 
found expression of MMP-2, MMP-9, MMP-14 
(MT1-MMP) and TIMP-2 and activation of MMP-2 
and MMP-9 in MM effusions (Sivertsen, 2006). 
MMP-2 and TIMP-2 mRNA expression was signiﬁ  -
cantly higher in peritoneal compared to pleural MM 
effusions (Sivertsen, 2006). The data in the above 
studies suggest a central role for MMP in the 
pathogenesis of MM. 
Adhesion Molecules and Other 
Membrane Receptors
Cell-cell adhesion is essential for normal cellular 
architecture and homeostasis. Cadherins, a family 
of Ca
2+-dependent integral membrane glycopro-
teins, are located at the cell-cell adherens junctions, 
where they mediate homophilic contact with neigh-
boring cells (Takeichi, 1991). Early data suggested 
that MM and AC cells exclusively express the 
epithelial and neural type of this molecule 
(E-cadherin and N-cadherin), respectively (Han, 
1997). These data have been shown to be erroneous 
by other investigators and us (Davidson, 2002; 
Abutaily, 2003; Sivertsen, 2006a; reviewed in 
Ordonez, 2003a). In fact, MM and serous AC are 
the two tumors that most strikingly exhibit co-
expression of different cadherins, including N-
cadherin, P-cadherin and E-cadherin (Sivertsen, 
2006a). Furthermore, MM cells in effusions 
upregulate the expression of these three cadherin 
molecules, suggesting that they play a role in 
metastasis and tumor progression (Sivertsen, 
2006b). This proﬁ  le may aid MM cells in combining 
conserved adhesion between tumor cells with the 
aggressive behavior of epithelial/epithelioid cells 
undergoing epithelial-mesenchymal transition 
(EMT), a process that is characterized by loss of 
E-cadherin and acquisition of N-cadherin (reviewed 
in De Wever, 2003). Interestingly, MM cells, 
including those of the epithelioid type, frequently 
express neural cell adhesion molecules (NCAM), 
members of a different family of adhesion mole-
cules that are expressed by neural and neuroendo-
crine cells and biphasic tumors (e.g. synovial 
sarcoma) (Lantuejoul, 2000). Seen together with 
the observation that MM express nerve growth 
factor receptors (Davidson, 2004), it is evident that 
this tumor is able to produce a remarkable array of 
molecules that have been previously thought to be 
lineage-speciﬁ  c.
Integrins, a second family of adhesion mole-
cules, are heterodimers consisting of noncovalently 
linked α and β subunits (Hynes, 1992). Integrins 
are fundamental regulators of cell growth, migra-
tion, survival and differentiation, and transduce 
signals from the extracellular environment to the 
gene expression machinery, thereby modulating 
signaling events initiated by growth factor recep-
tors (Howe, 1998; Dedhar, 2000). The extracellular 
matrix (ECM) integrin ligands include laminin, 
fibronectin, collagen, vitronectin, entactin, 
tenascin, and ﬁ  brinogen (Ruoslahti, 1991).
Klominek and co-workers previously showed 
that integrins are expressed in MM cell lines 
and that they mediate migration towards ECM 
proteins, including collagen type IV, fibronectin 
and laminin (Klominek, 1997). Koukoulis et al. 
studied 22 clinical MM specimens and found 
that the expression of most integrins, including 
the α6β4 integrin, in epithelioid MM is similar 
to previously reported patterns in AC of the 
lung, and often of other origins (Koukoulis, 
1997). We recently found that MM cells 
frequently express the αv and β1 integrin 
subunits, and that the α6 subunit, part of the 
α6β4 and α6β1 laminin receptors, is more 
frequently expressed in MM compared to 
ovarian and breast AC (Sigstad, 2005). In 
contrast, the 67kDa laminin receptor, a non-
integrin receptor that is frequently expressed in 
AC at all sites, is only rarely expressed in MM 
(Figure 1-C) (Reich, 2005). In view of the recent Biomarker Insights 2007: 2 176
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data of our group regarding the role of laminin 
receptors in tumor invasion and metastasis via 
activation of MMP-2 synthesis in malignant mela-
noma (Givant-Horwitz, 2004), it is conceivable 
that integrins, rather than the 67kDa receptor, may 
contribute to MMP production following binding 
to laminin in MM. 
Angiogenic Molecules and Other 
Growth Factors and Growth Factor 
Receptors
MM cells synthesize a large number of angiogenic 
molecules and other growth factors that may 
provide autocrine stimulation and relative inde-
pendence from the stromal and endothelial produc-
tion of these factors. The most extensively studied 
molecule in this context is VEGF. Expression of 
VEGF and its receptors ﬂ  t-1 and KDR has been 
shown in several studies, supporting the existence 
of this autocrine pathway in MM (Konig, 1999; 
Kumar-Singh, 1999; Ohta, 1999a; Konig, 2000; 
Strizzi, 2001a; Catalano, 2002; Davidson, 2004). 
A similar autocrine loop may exist for PDGF and 
its receptor PDGFR (Ascoli, 1995; Langerak, 
1996; Klominek, 1998a). PDGFR is of special 
interest since the α subunit of the receptor is the 
predominant one expressed in benign mesothelial 
cells, whereas expression of the β subunit is found 
in MM cell lines and clinical specimens (Versnel, 
1991; Ramael, 1992). Inhibition of PDGF-β using 
ribozyme technique results in reduced cell growth 
concomitantly to reduction in PDGF-β levels in 
the VAMT-1 cell line (Dorai, 1994). 
Additional pro-angiogenic molecules and 
growth factors that are synthesized by MM cell 
lines and clinical specimens are interleukin-8 
(IL-8) (Galffy, 1999; Davidson, 2004), bFGF 
(Strizzi, 2001b; Davidson, 2004), TGF-α (Langerak, 
1996), IGF (Hoang, 2004a), heparanase (Davidson, 
2004), thrombospondin (Ohta, 1999b), HGF/SF 
(Klominek, 1998b; Thirkettle, 2000) and several 
members of the Syndecan proteoglycan family 
(Kumar-Singh, 1998; Gulyas, 2003). MM cells 
express both EGFR (Dazzi, 1990; Pache, 1998; 
Manning, 2002; Cai, 2004; Destro, 2006) and its 
family member erbB-2 (Thirkettle, 2000), and 
EGFR expression has been shown to be closely 
related to the pathogenesis of asbestos injury 
(Pache, 1998; Manning, 2002). However, EGFR 
mutations were not detected in pleural MM 
(Destro, 2006).
Microvessel density is an independent prognostic 
marker in MM (Edwards, 2001). The clinical signiﬁ  -
cance of angiogenic molecule expression is suggested 
by the observed correlation between VEGF and bFGF 
and poor survival, with an opposite finding for 
Syndecan-1 (Kumar-Singh, 1999). EGFR expression 
correlates with worse survival in MM, but this ﬁ  nding 
loses signiﬁ  cance when histologic type (epithelioid 
vs. sarcomatoid) is taken into account (Dazzi, 1990). 
EGFR expression did not correlate with survival in a 
recent study (Destro, 2006).
We recently found that the activated nerve growth 
factor (NGF) receptor p-TrkA is more frequently 
expressed compared to p75, another NGF receptor 
that belongs to the tumor necrosis factor family, in 
MM, and that p-TrkA expression is signiﬁ  cantly 
higher in peritoneal MM compared to their pleural 
counterparts (Figures 1-D, 1-E). In addition, p-TrkA 
expression was marginally higher in effusions, while 
p75 expression was signiﬁ  cantly higher in solid MM 
(Davidson, 2004). This suggests that p-TrkA plays a 
signiﬁ  cant role in the biology of this disease and may 
be a relevant therapeutic target, especially for MM 
cells in effusions. 
We subsequently studied the anatomic site-
related expression of angiogenic molecules in MM, 
including VEGF, IL-8, bFGF and heparanase. 
Heparanase is an endoglycosidase that degrades 
heparan sulfate in the extracellular matrix (ECM) 
and cell surfaces and has a role in cancer metastasis 
and angiogenesis (Edovitsky, 2004). We found 
signiﬁ  cantly lower heparanase and bFGF expres-
sion in effusions compared with solid tumors 
(Davidson, 2004) (Figures 1-F, 1-G). This ﬁ  nding 
is comparable to our previous data in ovarian and 
breast carcinoma (Davidson, 2002b; Konstanti-
novsky, 2005) and suggests a reduced need for 
pro-angiogenic stimuli in effusions. 
The above data suggest that multiple growth factor-
initiated survival pathways may be activated in MM, 
although expression of some of these molecules may 
differ as function of the anatomic site and microenvi-
ronment. Studies investigating the therapeutic value 
of different receptor tyrosine kinase inhibitors are at 
advanced phase for many tumors, and inclusion of 
these agents in treatment protocols may be relevant 
for at least a subset of MM patients (Kindler, 2004). 
Apoptosis and Cell Cycle Molecules
As is the case for the majority of cancers, MM cells 
have deregulated response to pro-apoptotic signals Biomarker Insights 2007: 2 177
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and activate or deactivate cell cycle molecules that 
mediate sustained proliferation (reviewed in 
Fennell, 2004). Earlier work has shown that higher 
protein expression of the cell cycle inhibitor p27
kip1 
predicts longer survival in MM (Beer, 2001; 
Bongiovanni, 2001; Baldi, 2004), although this 
correlation was lost in multivariate analysis (Baldi, 
2004). Protein expression of p21, another cell cycle 
inhibitor, correlated with better survival in univar-
iate analysis in the latter study (Baldi, 2004), but 
showed no correlation with survival in an addi-
tional report (Isik, 2001). Interestingly, two inde-
pendent studies found that both high proliferation 
and high apoptosis correlate with worse survival 
in MM (Beer, 2000; Kahlos, 2000), the latter report 
showing that higher levels of the anti-oxidant 
enzyme manganese superoxide dismutase are 
associated with low proliferation (Kahlos, 2000). 
Data from the same group show that the anti-apop-
totic proteins Bcl-X and Mcl-1 and the pro-apop-
totic protein Bax are co-expressed in MM, with 
less frequent expression of another anti-apoptotic 
protein, Bcl-2 (Soini, 1999). A recent study simi-
larly showed co-expression of the anti-apoptotic 
proteins Bcl-2, Bcl-XL and Mcl-1, with variable 
loss of expression of the anti-apoptotic Bad, Bak, 
Bax, Bid and Bim (O’Kane, 2006). Expression of 
Fas ligand and loss of Bax were recently shown to 
correlate with shorter survival (Kokturk, 2005). 
Silencing methylation of TNF-related apoptosis-
inducing ligand (TRAIL) receptors has been found 
in various cancers, including clinical specimens 
and MM cell lines, documenting an important 
mechanism for the evasion of apoptosis 
(Shivapurkar, 2004). 
Recently, there has been growing focus on the 
role of the inhibitor of apoptosis (IAP) family in 
cancer. IAPs are caspase inhibitors that prevent 
apoptosis by speciﬁ  cally inhibiting caspases 3, 7 
and 9. To date, eight human IAPs have been iden-
tiﬁ  ed: cellular IAP1 (c-IAP1), cellular IAP2 (c-
IAP2), neuronal apoptosis inhibitory protein 
(NAIP), Survivin, X- linked IAP (XIAP), Apollon, 
testis-speciﬁ  c IAP (Ts-IAP), and Livin (Nachmias, 
2004). Frequent Survivin expression was found in 
MM cell lines and solid tumors, and blocking of 
Survivin by antisense oligonucleotides induced 
apoptosis in the MS-1 and H28 MM cell lines (Xia, 
2002). Survivin levels decreased following treat-
ment with Cisplatin, and treatment with anti-
Survivin oligonucleotides resulted in p53 activa-
tion and sensitization to apoptosis in the ZL34 cell 
line (Hopkins-Donaldson, 2006). Survivin mRNA 
expression was found to be elevated in pleural MM 
and inﬂ  ammatory pleuritis compared to normal 
pleura using real-time PCR (Falleni, 2005). c-IAP1 
expression was reported to be elevated in pleural 
MM compared to normal pleura and lung tissue, 
and antisense targeting of cIAP-1 resulted in 
caspase 9 cleavage and sensitization to apoptosis 
in the 94-589 cell line (Gordon, 2002a). 
We recently analyzed the expression of XIAP, 
Survivin and Livin in MM (Kleinberg, 2007). Using 
immunoblotting, we detected expression of XIAP 
and Survivin, but no expression of Livin, in effusion 
specimens. Immunohistochemical analysis of 112 
MM showed signiﬁ  cantly higher XIAP expression 
in peritoneal compared to pleural MM and in effu-
sions compared to solid lesions, with reduced 
expression of nuclear (postulated proliferation-
related) Survivin and the proliferation marker Ki-67 
in effusions compared to solid tumors. These data 
suggest that XIAP and Survivin, but not Livin, are 
frequently expressed in MM, and that the reduced 
nuclear Survivin expression in effusions may be 
related to lesser degree of proliferation. The upreg-
ulation of XIAP in MM effusions and in peritoneal 
mesothelioma suggests a major pro-survival role for 
this IAP member at these anatomic sites. 
These studies suggest that deregulation of cell 
death and survival by different mechanisms is 
frequent in MM, and that modulation of these 
pathways may be considered as a therapeutic 
modality in this cancer.
Differentiation Markers 
Two molecules that have received attention with 
respect to MM diagnosis and prognosis in recent 
years are the Wilms’ tumor 1 (WT1) gene and 
mesothelin. WT1 is a tumor suppressor gene local-
ized to chromosome 11 that is inactivated through 
mutation in 10% of Wilms’ tumors, a pediatric 
malignancy of renal origin. However, it is expressed 
in other tumors, such as leukemia, desmoplastic 
small round cell tumor and MM, and may function 
as both tumor suppressor and survival factor 
(Scharnhorst, 2001). WT1 expression in MM 
correlates with expression of Syndecan-1 (Kumar-
Singh 1998), but not of EGFR and IGFR, two 
transcriptional targets of WT1, or survival (Kumar-
Singh, 1997). WT1 does seem to have a role in 
differentiating MM from lung and other AC, 
though not from the closely-related serous AC of Biomarker Insights 2007: 2 178
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the ovary, the main differential diagnosis of MM 
within the peritoneal cavity (Kumar-Singh, 
1997).
Mesothelin is a 40-kDa cell surface glycopro-
tein that is synthesized from a 69-kDa precursor 
(Chang, 1996). Mesothelin binds to phosphatydi-
linositol, and dissociates from this signaling-related 
protein following treatment with phospholipase C 
(Chang, 1996). The biological role of mesothelin 
is uncertain at present, although it may have a role 
in cell adhesion (Chang, 1996). Mesothelin is 
frequently expressed on RM and MM, but despite 
earlier claims that its expression is limited to cells 
of mesothelial lineage (Urwin, 2000; Ordonez, 
2003b), has been shown to be expressed in several 
tumor types, including non-mucinous ovarian, lung 
and pancreatic AC (Miettinen, 2003; Ordonez, 
2003b). In view of the fact that lung and ovarian 
AC are two of the main differential diagnoses for 
MM, mesothelin appears to have limited value as 
a diagnostic marker. Mesothelin may yet have a 
role in other contexts. Serum mesothelin levels are 
elevated in MM, suggesting a role in early diag-
nosis of this tumor in high-risk populations 
(Robinson, 2003), a role as marker for monitoring 
treatment response (Hassan, 2006), and a potential 
target for tumor-related therapy (Hassan, 2004). A 
role in disease monitoring in MM was recently 
suggested also for megakaryocyte potentiation 
factor, a protein that is cleaved from a mesothelin 
precursor (Onda, 2006).
Intracellular Signaling
Signals originating from cell surface receptors are 
relayed to the nucleus via intracellular networks 
that are predominantly regulated through activation 
of kinases and phosphatases. Molecular events that 
occur following exposure to asbestos in vitro have 
been shown to affect mitogen-activated protein 
kinase (MAPK) signaling (Zanella, 1996; Ramos-
Nino, 2002; Shukla, 2003; Swain, 2004). Our 
group recently investigated protein expression 
(level) and phosphorylation status (activation) of 
the three MAPK members- extracellular-regulated 
kinase (ERK), c-Jun amino-terminal kinase (JNK) 
and high osmolarity glycerol response kinase (p38) 
in RM and MM specimens. Expression and activa-
tion of p38 (phospho-p38, p-p38) was found in the 
majority of specimens, with less frequent phos-
phorylation of ERK and JNK (Figure 1-H). MM 
and RM cells showed similar MAPK expression, 
activation and activation ratio. These data are the 
ﬁ  rst evidence of in vivo activation of MAPK in 
clinical MM and RM. The similar values in these 
two groups suggest that MAPK may not be 
involved in the transformation of benign to malig-
nant mesothelium, and therefore question the 
validity of MAPK as molecular therapeutic targets 
in MM (Vintman, 2005). 
Recent work has shown that Wnt-1, member of 
the Wnt family, is involved in inhibition of apop-
tosis in MM in vitro, and that inhibition of Wnt-1 
or its receptor Dishevelled induces apoptosis via 
JNK activation (You, 2004). These data are 
supported by the frequent inactivation through 
methylation of several secreted frizzled-related 
proteins, inhibitors of the Wnt pathway, in MM 
cell lines and clinical specimens (Lee, 2004). 
Although these studies provide important data 
regarding intracellular signaling in MM, our under-
standing of these pathways in clinical MM is 
minimal at present, and their complexity warrants 
further research. 
The Immune Response
The host response in cancer involves the production 
of an array of molecules designed to inhibit cancer 
cell growth and metastasis. In reality, this process 
often achieves the opposite effect due to the ability 
of tumor cells to utilize host-produced molecules as 
growth promoters and to evade immune response-
related mechanisms (Elenbaas, 2001). 
Asbestos inhibits the activity of lymphocyte-
activated killer cells (LAK) in vitro (Manning, 
1991). Tumor-infiltrating lymphocytes show 
reduced expression of activation markers and the 
production of cytokines is dysregulated in a murine 
MM model (Bielefeldt-Ohmann, 1994). IL-12 and 
IL-2 have been shown to induce an anti-tumor effect 
in experimental models (Caminschi, 1998; Porta, 
2000), while patient treatment with recombinant 
GM-CSF does not induce disease regression 
(Powell, 2006). However, anti-tumor effect was seen 
with use of soluble type II TGF-β receptor and 
interferon-β in experimental models (Odaka, 2001; 
Suzuki, 2004). Improved survival was observed 
following treatment of MM patients with Adeno-
virus-mediated herpes simplex virus thymidine 
kinase/ganciclovir gene therapy (Sterman, 2005). 
 We recently studied two aspects of the immune 
response in MM. In the ﬁ  rst study, we analyzed 
the expression of HLA-G, a non-classical major Biomarker Insights 2007: 2 179
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histocompatibility complex (MHC) class I that 
has been hypothesized to mediate cancer cell 
evasion of the host immune response (Algarra, 
2004). We found that MM cells only rarely 
express HLA-G, but that expression is signiﬁ  -
cantly higher in effusions (Figure 1-I), suggesting 
that cells at this site may utilize this surface 
molecule to evade the immune response in effu-
sions (Kleinberg, 2006). 
Chemokines are a family of small molecules 
that regulate the immune response and mediate 
several cancer-related events via speciﬁ  c receptors 
(Homey, 2002; Wilson, 2002). Chemokines 
produced by cancer and stromal cells attract 
lymphocytes and monocytes expressing their 
receptors to the tumor site. However, chemokine 
receptors have also been reported to be expressed 
on tumor cells, thereby creating an autocrine loop 
that mediates pro-growth signals (Homey, 2002). 
A recent study using a cytokine array system 
showed that the supernatant of cultured MM cells 
and the effusion ﬂ  uid contain 25 different chemo-
kines (Hegmans, 2006). We analyzed the charac-
teristics of the leukocyte inﬁ  ltrate expression and 
the expression of 5 chemokine receptors in MM 
and RM effusions. Chemokine receptors were 
frequently expressed on leukocytes in MM and 
RM effusions, but were infrequently present in 
MM cells and universally absent in RM cells. This 
ﬁ  nding suggests a major role for an autocrine 
chemokine pathway in leukocytes, but not in MM 
cells. We additionally found increased monocyte 
infiltration and monocyte chemokine receptor 
expression in MM compared to RM effusions, 
suggesting these cells may have a tumor-promoting 
rather than inhibiting effect (Davidson, 2007). 
High-Throughput Methods
Advances in molecular techniques allow for multi-
parameter analysis of genes (comparative genomic 
hybridization, CGH), mRNA transcripts (cDNA 
arrays) and proteins (proteomics). Among these 
methods, cDNA analysis is the one that has been most 
often used in studies of MM. Comparative analysis 
of clinical specimens and MM cell lines identiﬁ  ed 
candidate gene products that are upregulated in the 
former group, such as matriptase (Hoang, 2004b). 
Comparative analysis of lung AC and pleural 
MM identiﬁ  ed several markers that are differen-
tially expressed by these two tumors, including 
calretinin and thyroid transcription factor-1 (TTF-
1), that are commonly used in the diagnostic 
setting (Gordon, 2002b). Two studies in which 
MM specimens were compared to benign pleura 
and/or RM-derived cell lines have revealed a large 
number of genes that are differentially expressed 
in these two conditions (Singhal, 2003; Kettunen, 
2005). Singhal et al. found 166 genes that were 
upregulated and 26 that were downregulated in 
MM, including cytoskeletal elements (e.g. 
annexins, integrins, keratins), molecules involved 
in protein synthesis and in metabolic pathways 
and gene products deﬁ  ned as having therapeutic 
and prognostic implications (Singhal, 2003). 
Kettunen et al. analyzed the expression of 588 
gene products and found several that were over-
expressed in MM compared to benign mesothe-
lium (the collagen 1A2 chain and the β4 integrin 
subunit) and RM-derived cell lines (e.g. ezrin, 
bFGF, the tPA and uPA plasminogen activators, 
N-cadherin, cytokeratin 7), and others that were 
reduced in malignant cells (TRAIL, cytokeratin 
19, α3 integrin subunit) (Kettunen, 2005). The 
latter study also reported histologic type-speciﬁ  c 
upregulation of gene products (e.g. P-cadherin in 
epithelioid MM; MMP-9 and tPA in sarcomatoid 
MM), thus providing molecular correlates for 
these morphologic differences (Kettunen, 2005). 
Two recent studies focused on the prognostic value 
of different molecules in MM (Gordon, 2003; 
Pass, 2004). Gordon et al. found several mRNAs 
that are expressed in higher levels in MM cases 
with better (e.g. hyaluronan synthase) and worse 
(e.g. insulin-like growth factor-binding protein-3; 
IGFBP-3) outcome (Gordon, 2003). Pass et al. 
found 27 genes with predictive value using 
two different statistical tests (dChip and SAM), 
including the α6 integrin subunit, the metastasis 
suppressor nm23, ﬁ  broblast growth factor 7 and 
IGFBP5 (Pass, 2004). A recent study by Lopez-
Rios et al. identiﬁ  ed several new genes that aid 
in the differentiation between sarcomatoid 
and epithelioid MM, including Uroplakin 1B 
and 3B, kallikrein 11, claudin 15 and Annexin A9, 
all more highly expressed in epithelioid MM 
(Lopez-Rios, 2006). Of note, the authors report 
relatively low predictive value for survival for this 
method, with no signiﬁ  cant additive power to data 
obtained by standard clinicopathologic variables 
and p16/CDNK2A status, suggesting that global 
gene expression proﬁ  ling may have a greater role 
as a research tool than in clinical practice (Lopez-
Rios, 2006). Biomarker Insights 2007: 2 180
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Figure 1. A: H&E staining of a cell block section from a pleural mesothelioma; B: PAP-stained smear from the same specimen; C: Protein 
expression of the 67kDa laminin receptor, a rare event in mesothelioma; D: p-TrkA membrane expression in a pleural mesothelioma; 
E: Focal p75 expression in the same specimen. Only one cell expresses this receptor; F-G: Heparanase (F) and bFGF (G) cytoplasmic 
expression in two pleural mesotheliomas; H: Nuclear expression of activated ERK (p-ERK) in the pleural mesothelioma shown in ﬁ  gures 
A-B; I: membrane expression of HLA-G in a pleural mesothelioma effusion. 
Along this line, our group recently performed 
a cDNA analysis comparing diffuse malignant 
peritoneal mesothelioma (DMPM) and ovarian 
carcinoma cells in effusions, two tumors with 
common histogenesis that share expression of 
many diagnostic and differentiation markers. In 
this analysis, we identiﬁ  ed 189 genes that are 
differentially expressed in these cancers, including 
higher gene expression of calretinin, vitronectin, 
claudin 15, α4 laminin and hyaluronan synthase 1 Biomarker Insights 2007: 2 181
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in DMPM, and higher IGF-II, IGFBP-3, cyclin E1, 
folate receptors 1 and 3, RAB25, MUC4, endo-
thelin-1, CD24, kallikreins 6/7/8, claudins 3/4/6, 
Notch3 and MMP-7 expression in ovarian carci-
noma (Davidson, 2006). 
How this novel knowledge will impact on the 
diagnosis and clinical management of MM is yet 
to be seen. One area that has not yet received sufﬁ  -
cient attention is large-scale protein analysis. 
Although data on mRNA level reﬂ  ect the transcrip-
tional activity of MM cells, protein analysis is more 
directly related to the biological activity of these 
molecules. Hegmans et al. recently studied the 
protein profile of exosomes, small membrane 
vesicles that are secreted into the ECM, in MM 
cell lines using the matrix-assisted laser desorption 
ionization time-of-flight (MALDI-TOF). The 
authors identiﬁ  ed several proteins that are secreted 
by MM cells in vitro, including MHC class I anti-
gens, heat shock proteins (HSC70, HSP90), and 
cytoskeletal proteins (ezrin, actinin-4) (Hegmans, 
2004). If conﬁ  rmed in clinical material, these 
proteins may teach us more about the microenvi-
ronment of MM and provide new molecular targets 
for directed therapy. 
Concluding Remarks
The rise in the incidence of MM presents a growing 
health problem and emphasizes the need for 
improved diagnosis, prognostication and treatment 
in this cancer. The body of work reviewed in this 
paper documents the growing effort to understand 
the biology of this disease and its genetic make-up, 
and to deﬁ  ne the biological characteristics that 
favor the survival of MM cells. Our own data reveal 
differences between peritoneal and pleural MM, 
and between MM cells in solid lesions and effu-
sions, suggesting that the tumor microenvironment 
in part regulates the synthesis of cancer-associated 
molecules in MM. 
To date, our understanding of MM biology and 
the efforts to target key-molecules in this disease 
have not signiﬁ  cantly altered the poor survival 
associated with this cancer type. However, knowl-
edge regarding the biology of MM is being more 
frequently translated into new treatment approaches. 
Vogelzang et al. recently reviewed new agents that 
under evaluation for the treatment of MM, including 
EGFR, PDGFR, VEGF and HGF inhibitors, inhib-
itors of mTOR, a downstream molecule of the 
PI3K/AKT pathway, and inhibitors of the protea-
some/ubiquitin pathway (Vogelzang, 2005). 
Although recent results in clinical trials using the 
tyrosine kinase receptor inhibitor imatinib mesylate, 
which targets PDGFR and c-Kit, have not been 
encouraging (Mathy, 2005; Porta, 2007), it is to be 
hoped that the common effort of medical and 
research disciplines will in the future allow us to 
achieve more success in treating this highly lethal 
tumor. 
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